Journals / Marmara Medical Journal / 2015 / Volume: 24 Issue: 1

-

Periferik Hematopoietik Kök Hücre Nakli Yapılan Hastalarda Kök Hücre Mobilizasyonunu Etkileyen Faktörler

Pages
—
Publication Date
2015-04-21
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗

Abstract

-

Özet

Amaç: Otolog kök hücre transplantasyonunun başarısı yeterli sayıda kök hücrenin infüzyonuna bağlıdır. Bu nedenle kök hücre mobilizasyonunu etkileyen faktörlerin tanımlanması önem taşımaktadır. Çalışmamızın amacı, otolog kök hücre nakli uygulanan hastalarda kök hücre mobilizasyonunu etkileyen faktörleri belirlemektir. Hastalar ve Yöntemler: Otolog kök hücre nakli yapılan 143 hasta ve bu hastalara uygulanan 169 kök hücre aferez işlemi retrospektif olarak değerlendirildi. Bulgular: Kök hücre mobilizasyonu için 89 (%52.7) hastada Filgrastim, 80 (%47.3) hastada Lenograstim kullanıldı. Aferez işleminde 69 (%40.8) hastada Fresenius, 100 (%59.2) hastada Haemonetics cihazı kullanıldı. Tek değişkenli analizlerde tanı (p=0.005), aferez öncesi tedavi sayısı (p:0.0004), tanıdan afereze kadar geçen süre (p:0.02), aferezin 1. günündeki lökosit ve CD34+ hücre sayısı (p:0.0001; p:0.0005), filgrastim kullanımı (p=0.00004) ve fresenius cihazının kullanımı (p:0.007)'nın kök hücre mobilizasyonunu etkileyen faktörler olduğu görüldü. Çok değişkenli analizlerde ise en önemli faktörlerin tanı (p=0.01), filgrastim kullanımı (p=0.001), fresenius cihazının kullanımı (p=0.03) ve aferezin 1. günündeki lökosit sayısı (p=0.006) olduğu saptandı. Sonuç: Çalışmamızda tanı, filgrastim ile mobilizasyon, fresenius cihazının kullanılması, ve aferezin 1. gününde periferik kandaki WBC sayısının kök hücre mobilizasyonunu etkileyen en önemli değişkenler olduğu saptanmıştır. Anahtar Kelimeler : Kök hücre mobilizasyonu, Hematopoetik periferal kök hücre nakli, Filgrastim, Lenograstim, Aferez

🔖

Cite This Article

Kaygusuz, İ., Kantarcıoğlu, B., Toptaş, T., Yılmaz, G., Adıgüzel, C., Tuğlular, T. F., Demiralp, E., Bayık, M. (2015). -. Marmara Medical Journal, Volume: 24 Issue: 1. https://ajindex.com/articles/1286993

References (139)

  1. Cottler-Fox M, Lapidot T, Petit I, et al. Stem cell
  2. mobilization. Hematology 2003;419-437.
  3. Lee JL, Kim SB, Lee GW, et al. Clinical
  4. usefulness of the hematopoietic progenitor cell
  5. counts in predicting the optimal timing of
  6. peripheral blood stem cell harvest. J Korean
  7. Med Sci 2003; 18: 27-35. doi: 10.1111/j.0041-
  8. 04166.x
  9. Rainer Moog. Management strategies for poor
  10. peripheral blood stem cell mobilization. Transfus
  11. Apher Sci. 2008; 38: 229–236. doi:
  12. j.transci.2008.04.002
  13. Mendrone A Jr, Arrais CA, Saboya R, Chamone
  14. DA, Frederico Luiz Dulley FL. Factors affecting
  15. hematopoietic progenitor cell mobilization: An
  16. analysis of 307 patients. Transfus Apher Sci.; 39: 187–192. doi:
  17. j.transci.2008.09.012
  18. Arslan O, Moog R. Mobilization of peripheral
  19. blood stem cells. Transfusion and Apheresis
  20. Science 2007; 37: 179–185. doi:
  21. j.transci.2007.08.002
  22. Weaver CH, Schwartzberg LS, Birch R, et al.
  23. Collection of peripheral blood progenitor cells
  24. after the administration of cyclophosphamide,
  25. etoposide, and granulocyte-colony-stimulating
  26. factor: an analysis of 497 patients. Transfusion;37:896–903. doi:10.1046/j.1537-
  27. 37997454014.x
  28. Haas R, Möhle R, Frühauf S, et al. Patient
  29. characteristics associated with successful
  30. mobilizing and autografting of peripheral
  31. progenitor cells in malignant lymphoma. Blood;83:3787–3794.
  32. Kasparu H, Krieger O, Girschikofsky M, Kolb A,
  33. Bettelheim P, Lutz D. Factors influencing the
  34. timing of peripheral blood stem cell collection
  35. (PBSC). Transfus Apheresis Sci 1996;17:595–
  36. Ikeda K, Kozuka T, Harada M. Factors for PBPC
  37. collection efficiency and collection predictors.
  38. Transfus Apher Sci. 2004;31: 245–259. doi:
  39. j.transci.2004.09.008
  40. Elliott C, Samson DM, Armitage S, et al. When
  41. to harvest peripheral-blood stem cells after
  42. mobilization therapy: Prediction of CD34-positive
  43. cell yield by preceding day CD34-positive
  44. concentration in peripheral blood. J Clin Oncol; 14:970-973.
  45. Gidron A, Singh V, Egan K, Mehta J.
  46. Significance of low peripheral blood CD34ş cell
  47. numbers prior to leukapheresis: what should the
  48. threshold required for apheresis be? Bone
  49. Marrow Transplant 2008; 42: 439–442.
  50. Mehta J, Oyama Y, Winter J, et al. CD34+ cell
  51. collection efficiency does not correlate with the
  52. pre-leukapheresis hematocrit. Bone Marrow
  53. Transplant 2001; 28: 597–601.
  54. Gidron A, Verma A, Doyle M, et al. Can the stem
  55. cell mobilization technique influence CD34+ cell
  56. collection efficiency of leukapheresis procedures
  57. in patients with hematologic malignancies? Bone
  58. Marrow Transplant 2005; 35: 243–246. doi:
  59. sj.bmt.1704781
  60. Schots R, Van Riet I, Damianos S, et al. The
  61. absolute number of circulating CD34+ cells
  62. predicts the number of hematopoietic stem cells
  63. that can be predicted by apheresis. Bone
  64. Marrow Transplant 1996;17:509-15.
  65. Schwella N, Beyer J, Schwaner I, et al. Impact of
  66. preleukapheresis cell counts on collection
  67. results and correlation of progenitor cell dose
  68. with engraftment after high-dose chemotherapy
  69. in patients with germ-cell cancer. J Clin Oncol;14:1114-1121.
  70. Mohle R, Murea S, Pforsich M, Witt B, Haas R.
  71. Estimation of the progenitor cell yield in a
  72. leukapheresis product by previous measurement
  73. of CD34+ cells in the peripheral blood. Vox Sang;71:90-196.
  74. I. KAYGUSUZ, et al
  75. Factors affecting stem cell mobilization
  76. Marmara Medical Journal 2011; 24 (1):31-37
  77. Ford C, Chan K, Reilly W, Peterson F. An
  78. evaluation of predictive factors for CD34+ cell
  79. harvest yields from patients mobilized with
  80. chemotherapy and growth factors. Transfusion;43:622-625. doi: 10.1046/j.1537-
  81. 00376.x
  82. Moncada V, Bolan C, Yau Y, Leitman S.
  83. Analysis of PBPC yields during large volume
  84. leukapheresis of subjects with a poor
  85. mobilization response to filgrastim. Transfusion;43:495-501. doi: 10.1046/j.1537-
  86. 00361.x
  87. Ravagnani F, Siena S, De Reys S, et al.
  88. Improved collection of mobilized CD34+
  89. hematopoietic progenitor cells by a novel
  90. automated leukapheresis system. Transfusion;39:48–55. doi: 10.1046/j.1537-
  91. 39199116894.x
  92. Bambi F, Faulkner LB, Azzari C, et al. Pediatric
  93. peripheral blood progenitor cell collection:
  94. haemonetics MCS 3P versus COBE Spectra
  95. versus Fresenius AS104. Transfusion 1998
  96. Jan;38(1):70-74.
  97. Kishita M. Stability of granulocyte colonystimulating
  98. factor (G-CSF) in serum. Clin Rep;26:221–224.
  99. Pedrazzoli P, Gibelli N, Pavesi L, et al. Effects of
  100. glycosylated and non-glycosylated G-CSFs,
  101. alone and in combination with other cytokines,
  102. on the growth of human progenitor cells.
  103. Anticancer Res 1996;16:1781–1785.
  104. Mire-Sluis AR, Das RG, Thorpe R. The
  105. international standard for granulocyte colony
  106. stimulating factor (G-CSF). Evaluation in an
  107. international collaborative study. Participants of
  108. the Collaborative Study. J Immunol Methods;179:117–126.
  109. Nissen C, dalle Carbonare Y, Moser Y. In vitro
  110. comparison of the biological potency of
  111. glycosylated versus non-glycosylated rG-CSF.
  112. Drug Invest 1994;7:346–352.
  113. Höglund M, Smedmyr B, Bengtsson M, et al.
  114. Mobilization of CD34+ cells by glycosylated and
  115. nonglycosylated G-CSF in healthy donors –
  116. comparative study. Eur J Haematol;59:177–183. doi: 10.1111/j.1600-
  117. tb00972.x
  118. Watts MJ, Addison I, Long SG, et al. Crossover
  119. study of the haematological effects and
  120. pharmacokinetics of glycosylated and nonglycosylated
  121. G-CSF in healthy volunteers. Br J
  122. Haematol 1997;98:474–479. doi:
  123. j.1365-2141.1997.2393053
  124. Schiødt I, Knudsen LM, Jensen L, et al. Flow
  125. cytometry comparison of CD341 subsets in bone
  126. marrow and peripheral blood after priming with
  127. glycosylated or non-glycosylated rhG-CSF. Bone
  128. Marrow Transplant 1998; 21:1167–1169.
  129. Tomblyn M, Burns LJ, Blazar B, et al. Difficult
  130. stem cell mobilization despite adequate CD34+
  131. cell dose predicts shortened progression free
  132. and overall survival after autologous HSCT for
  133. lymphoma. Bone Marrow Transplant 2007;:111–118. doi: 10.1038/sj.bmt.1705708
  134. Dreger P, Kloss M, Petersen B, et al. Autologous
  135. progenitor cell transplantation: Prior exposure to
  136. stem cell-toxic drugs determines yield and
  137. engraftment of peripheral blood progenitor cell
  138. but not of bone marrow grafts. Blood 1995;
  139. : 3970-3978.